Published in Biotech Business Week, March 28th, 2005
The NOVA (NOGA Delivery of VEGF for Angina) trial will evaluate the effects of BIOBYPASS on exercise tolerance, heart function, symptoms, and quality of life in approximately 129 patients suffering from moderate-to-severe chest pain due to advanced coronary artery disease.
Jens Kastrup, MD, at Rigshospitalet in Copenhagen, Denmark, is the principal investigator for the NOVA trial. Two medical centers have begun enrollment, under the direction of Dr. Erik Jorgensen at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.